Page 27 - Astrazeneca

Covid-19: AstraZeneca delivers but can't match rivals, here's what we know

The Astra-Oxford vaccine on average prevented 70% of cases in large trials in the U.K. and Brazil

India to Brazil, Astra-Oxford vaccine is key to many nations' Covid plan

The Astra vaccine costs a fraction of the price set by Pfizer; it should be easier to deploy far and wide than other shots.

Oxford-AstraZeneca Covid-19 vaccine shows immune response in older adults

The vaccine causes few side effects and provokes a response in T-cells that target the virus within 14 days of the first dose and a protective antibody response within 28 days of the booster dose

Covid-19 vaccine unlikely before early or mid-2021: WHO Southeast Asia head

Even the front-runners among vaccine companies would take at least a few months to complete Phase-III trials and evaluate the efficacy and safety of individual vaccines

Coronavirus updates: 2nd wave in Maharashtra 'soon' & the vaccine challenge

The Maharashtra government has said that the the second wave of coronavirus is expected in the state in January-February based on what is happening in Europe

AstraZeneca's Covid-19 vaccine to begin clinical trials in China this year

AstraZeneca plans to start early and mid-stage clinical trials of its Covid-19 vaccine candidate in China this year, a senior executive said, as it prepares a global rollout of the vaccine

AstraZeneca beats Q3 sales estimate on strong demand; backs 2020 outlook

Product sales, which exclude payments from collaborations, rose 7 per cent to $6.52 billion for the three months ended September 30 on a constant-currency basis

Bharat Biotech's coronavirus vaccine may be launched in February

Moderna and AstraZeneca are close behind the largest US drugmaker and are likely to have early data on their vaccine candidates before the end of the year.

AstraZeneca to bring non-US vaccine data before FDA for emergency approval

If and when AstraZeneca reaches the first statistically reliable efficacy and safety results from those trials, based on more than 25,000 volunteers in total, it would present them to the US Food and

AstraZeneca Pharma India Q2 net profit up 83% at Rs 26.33 crore

Drug firm AstraZeneca Pharma India on Thursday reported an 83.48 per cent rise in its net profit at Rs 26.33 crore for the quarter ended September 2020. The company had posted a net profit of Rs 14.41 crore for the corresponding period of the previous fiscal, it said in a filing to the BSE. Revenue from operations stood at Rs 209.47 crore for the quarter under consideration. It was Rs 208.48 crore for the same period a year ago, it added. Shares of AstraZeneca Pharma India closed at Rs4,295.80per scrip on the BSE, up 0.40 per cent from their previous close.

Britain prepares for Covid-19 vaccine as Oxford forecasts result this year

There are more than 200 candidates under development and the vaccine being developed by Oxford and licensed to British drugmaker AstraZeneca is seen as a front-runner

UK starts accelerated review for AstraZeneca's potential Covid-19 vaccine

"We confirm the MHRA's (Medicines and Healthcare Products Regulatory Agency) rolling review of our potential Covid-19 vaccine," an AstraZeneca spokesman said

UK starts real-time review of Moderna's Covid-19 vaccine candidate

Moderna said earlier this month it was going to apply for real-time reviews of its experimental Covid-19 vaccine to Europe, following rolling reviews of shots of its rivals Pfizer Inc and AstraZeneca

Oxford Covid-19 vaccine prompts immune response among adults: AstraZeneca

The Financial Times reported that the vaccine, being developed by Oxford and AstraZeneca, triggers protective antibodies and T-cells in older age groups. It cited two people familiar with the finding

Johnson & Johnson, AstraZeneca to resume trial for Covid-19 vaccine

Earlier, AstraZeneca said it had been cleared by the FDA to restart a trial that had been halted in the U.S. after a volunteer participating in a U.K. trial of the shot had fallen ill

AstraZeneca resumes US Covid vaccine trial; J&J prepares for same next week

(Reuters) - AstraZeneca Plc has resumed the U.S. trial of its experimental COVID-19 vaccine after approval by regulators, and Johnson & Johnson is preparing to resume its trial on Monday or Tuesday, the companies said on Friday.

AstraZeneca resumes US Covid-19 vaccine trial, optimism seen for J&J

AstraZeneca's US trial was paused on September 6 after a report of a serious neurological illness, believed to be transverse myelitis, in a participant in the company's UK trial

AstraZeneca's volunteer who died didn't get Covid-19 vaccine: Report

Brazil's health authority Anvisa said it had been informed on Monday of the study volunteer's death and had received a partial report from an international committee assessing the trial's safety

AstraZeneca Covid-19 vaccine trial volunteer dies, did not receive dose

Oxford confirmed the plan to keep testing

World Coronavirus Dispatch: China finds infection risk in frozen food packs

Brazil's weekly cases lowest in 5 months, New Zealand has first community case in three weeks, Israel eases curbs and other pandemic-related news across the globe